At a glance
ClinicalIndex Comparison RecordN/AUnknown· 129 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China
In Brief
An observational study for Nonsmall Cell Lung Cancer and Adenocarcinoma. Targeting 129 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNonsmall Cell Lung Cancer, Adenocarcinoma
CountriesChina
CollaboratorsShanghai Chest Hospital, Baotou Cancer Hospital
Timeline
N/AUnknownOverdue
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionOct 2018
Study CompletionDec 2018
TodayJul 2026
First PostedDec 2, 2016
Enrollment StartNov 1, 2016
Primary CompletionOct 1, 2018
Study CompletionDec 1, 2018
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 9.6 years ago